Retatrutide 40mg | 10-Vial Kit | 400mg Total | Triple Agonist GIP/GLP-1/Glucagon
About this compound
Retatrutide 40mg — triple GLP-1R/GIPR/GCGR agonist, 24.2% Phase 2 weight loss. ≥99% HPLC, Janoshik COA. 10-vial kit. Research use only.
Certificate of Analysis
Lab tested by JanoshikIndependent third-party HPLC / mass-spec analysis for Retatrutide 40mg | 10-Vial Kit | 400mg Total | Triple Agonist GIP/GLP-1/Glucagon. Each report carries a unique key you can verify directly with the lab.
Retatrutide 40mg | 10-Vial Kit | 400mg Total | Triple Agonist GIP/GLP-1/Glucagon
Retatrutide 40mg — triple GLP-1R/GIPR/GCGR agonist, 24.2% Phase 2 weight loss.
40mg ·single research unit
Preorder
This size is not listed in the current warehouse stock sheet. Order now and dispatch origin will be confirmed before fulfilment.
Crypto checkout - discreet, tracked shipping
Research Use Only - not for human or veterinary consumption. Handling restricted to qualified researchers.
- Form
- Lyophilized powder
- Stock status
- Preorder
- Shipping
- Confirmed before fulfilment
- Payment
- USDC · USDT
Related compounds
Retatrutide 10mg | 20-Vial Kit | Triple Agonist GIP/GLP-1/Glucagon
Retatrutide 10mg | 20-Vial Kit | Triple Agonist GIP/GLP-1/Glucagon
QSC Retatrutide (Triple GLP-1R/GIPR/GCGR agonist (LY3437943)) — ≥99% HPLC purity, MS confirmed, Janoshik COA.
Tirzepatide 30mg | 20-Vial Kit | Dual GIP/GLP-1 Agonist
Tirzepatide 30mg | 20-Vial Kit | Dual GIP/GLP-1 Agonist
QSC Tirzepatide (Dual GIP+GLP-1 receptor agonist) — ≥99% HPLC purity, MS confirmed, Janoshik COA.
Semaglutide 30mg | 10-Vial Kit | 300mg Total | GLP-1 Receptor Agonist
Semaglutide 30mg | 10-Vial Kit | 300mg Total | GLP-1 Receptor Agonist
Semaglutide 30mg — high-dose GLP-1R agonist research vial.
Adipotide 2mg | 10-Vial Kit | 20mg Total | Proapoptotic Adipose Peptide
Adipotide 2mg | 10-Vial Kit | 20mg Total | Proapoptotic Adipose Peptide
Adipotide 2mg | 10-Vial Kit — Proapoptotic peptidomimetic — selectively induces apoptosis in prohibitin-expressing white adipose vasculature, causing…